SC News and Research

Let’s Talk About Self-Care: Living Well with Sickle Cell — with Tanya Gentry

Leave a Comment / Living with Sickle Cell, SC News and Research, Videos /

Self-care isn’t selfish — it’s survival. Join me and Tanya Gentry for ‘Let’s Talk About Self-Care: Living Well with Sickle Cell,’ presented by Building Bridges Sickle Cell Disease Foundation. Tuesday, October 13 · 5 PM PSTVia Zoom, streaming on Facebook LiveSponsored by Pfizer Come as you are. Leave with something new. What’s ONE self-care habit

Let’s Talk About Self-Care: Living Well with Sickle Cell — with Tanya Gentry Read More »

Close-up of a scientist's hands in gloves analyzing a blood sample in a laboratory setting.

Mitapivat Decision Due November 1: A Pill, Not a Cure — But a Step Forward

Leave a Comment / SC News and Research /

By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. The U.S. Food and Drug Administration’s decision on mitapivat, a pill for sickle cell disease, is due November 1, 2026. Mitapivat is not a cure. In Phase 3 trials, however, it raised hemoglobin levels — and for people living crisis to crisis,

Mitapivat Decision Due November 1: A Pill, Not a Cure — But a Step Forward Read More »

A neatly arranged blister pack containing pink tablets on a solid purple surface.

Hydroxyurea Linked to Fewer Crises in Guinea: What a 102-Patient Study Shows

Leave a Comment / Advocacy and Activism, SC News and Research /

By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. A study from Conakry, Guinea, has found hydroxyurea linked to fewer sickle cell crises — welcome evidence from a region where sickle cell disease affects so many families, and where access to treatment is often limited. The study followed 102 patients and

Hydroxyurea Linked to Fewer Crises in Guinea: What a 102-Patient Study Shows Read More »

A female scientist conducting research in a well-equipped laboratory, focusing on chemical analysis.

A First in the UK: A Patient Completes Gene-Editing Therapy for Sickle Cell Disease

Leave a Comment / SC News and Research /

By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. Aisha has become the first patient in the United Kingdom to complete gene-editing therapy for sickle cell disease — and is now living without sickle cell crises. This milestone, reported by Manchester University NHS Foundation Trust, matters far beyond one hospital. For

A First in the UK: A Patient Completes Gene-Editing Therapy for Sickle Cell Disease Read More »

Sickle Cell Trait 360 (SCT360): Full Sickle
Hemoglobinopathy Specturm Education

SC News and Research /

PRESENTED BY : As One Foundation, The Sickle Cell Community Consortium, The Chris ‘CJ’Foundation,WHATZ DA COUNT on SCT, and NSCRXPTION CO. Friday, August 19, 2022 8:45 AM – 3:30 PM (Central) Series Objectives Identify and understand the disorder of sickle cell trait along the spectrum of sickle hemoglobinopathies. Integrate risk factors of sickle cell trait

Sickle Cell Trait 360 (SCT360): Full Sickle
Hemoglobinopathy Specturm Education Read More »

THE 16TH ANNUAL SICKLE CELL DISEASE RESEARCH AND EDUCATIONAL SYMPOSIUM AND 45TH NATIONAL SICKLE CELL DISEASE SCIENTIFIC MEETING

Newest Features, Resources, SC News and Research /

5th Annual Sickle Cell Disease Access To Care Summit Friday, June 10th Healthcare Access in Sickle Cell Disease Plenary Session Curative Therapies & Gene Therapy Education Session The Patient Symposium 16th Annual Sickle Cell Disease Research and Educational Symposium Saturday, June 11th Education sessions on HealthTech, Healthcare Screening, Alternative & Adjunct Therapies Keynote Speaker Presentation

THE 16TH ANNUAL SICKLE CELL DISEASE RESEARCH AND EDUCATIONAL SYMPOSIUM AND 45TH NATIONAL SICKLE CELL DISEASE SCIENTIFIC MEETING Read More »

Sickle Cell Warriors Inc

New data for Vertex and CRISPR Therapeutics

Newest Features, SC News and Research /

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting – Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion – – Sickle cell disease: All seven patients were free of vaso-occlusive crises after

New data for Vertex and CRISPR Therapeutics Read More »

Sickle Cell Warriors Inc

Are You at Risk for Multiple Myeloma?

Living with Sickle Cell, SC News and Research /

Multiple myeloma is a relatively rare cancer that develops in the bone marrow. As the cancerous plasma cells accumulate in the marrow, they crowd out other healthy blood cells. Unfortunately, the symptoms including bone pain, mental fogginess, excessive thirst may develop slowly over time and don’t usually appear until the disease reaches an advanced stage. In

Are You at Risk for Multiple Myeloma? Read More »

Donate
Donate
Shopping Cart
Scroll to Top
Secret Link